CA3196119A1 - A magl inhibitor - Google Patents
A magl inhibitorInfo
- Publication number
- CA3196119A1 CA3196119A1 CA3196119A CA3196119A CA3196119A1 CA 3196119 A1 CA3196119 A1 CA 3196119A1 CA 3196119 A CA3196119 A CA 3196119A CA 3196119 A CA3196119 A CA 3196119A CA 3196119 A1 CA3196119 A1 CA 3196119A1
- Authority
- CA
- Canada
- Prior art keywords
- azaspiro
- octane
- hexafluoropropan
- carboxylate
- carbamoy1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113662P | 2020-11-13 | 2020-11-13 | |
| US63/113,662 | 2020-11-13 | ||
| PCT/EP2021/081522 WO2022101412A1 (en) | 2020-11-13 | 2021-11-12 | A magl inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196119A1 true CA3196119A1 (en) | 2022-05-19 |
Family
ID=78709459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196119A Pending CA3196119A1 (en) | 2020-11-13 | 2021-11-12 | A magl inhibitor |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11434222B2 (https=) |
| EP (2) | EP4574150A3 (https=) |
| JP (1) | JP2023549051A (https=) |
| KR (1) | KR20230107225A (https=) |
| CN (2) | CN116547274B (https=) |
| AR (1) | AR124057A1 (https=) |
| AU (1) | AU2021379081A1 (https=) |
| CA (1) | CA3196119A1 (https=) |
| CL (1) | CL2023001339A1 (https=) |
| CO (1) | CO2023004649A2 (https=) |
| CR (1) | CR20230203A (https=) |
| DK (1) | DK4244208T3 (https=) |
| DO (1) | DOP2023000086A (https=) |
| ES (1) | ES3025484T3 (https=) |
| FI (1) | FI4244208T3 (https=) |
| GE (2) | GEP20257794B (https=) |
| HR (1) | HRP20250644T1 (https=) |
| HU (1) | HUE071543T2 (https=) |
| IL (1) | IL301818B1 (https=) |
| JO (1) | JOP20230091A1 (https=) |
| LT (1) | LT4244208T (https=) |
| MA (1) | MA62148B1 (https=) |
| MX (1) | MX2023005576A (https=) |
| PL (1) | PL4244208T3 (https=) |
| PT (1) | PT4244208T (https=) |
| RS (1) | RS66839B1 (https=) |
| SA (1) | SA523440403B1 (https=) |
| SI (1) | SI4244208T1 (https=) |
| TW (1) | TWI904281B (https=) |
| UA (1) | UA130186C2 (https=) |
| UY (1) | UY39516A (https=) |
| WO (1) | WO2022101412A1 (https=) |
| ZA (1) | ZA202304134B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2429991A (en) * | 2005-09-07 | 2007-03-14 | Alan Barrows | Water powered impulsive unit |
| US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| FR2960875B1 (fr) * | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| US9487495B2 (en) | 2012-01-06 | 2016-11-08 | The Scripts Research Institute | Carbamate compounds and of making and using same |
| US9822129B2 (en) * | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| MX368615B (es) | 2012-09-25 | 2019-10-09 | Hoffmann La Roche | Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos. |
| CA2917050A1 (en) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| CU24442B1 (es) | 2014-04-04 | 2019-09-04 | X Rx Inc | Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina |
| ES2878041T3 (es) | 2015-03-18 | 2021-11-18 | H Lundbeck As | Carbamatos de piperazina y métodos para prepararlos y usarlos |
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| EP3340988B1 (en) * | 2015-11-12 | 2025-04-09 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| CR20200088A (es) * | 2017-08-29 | 2020-04-08 | Lundbeck La Jolla Research Center Inc | Compuestos espirocíclicos y sus métodos de preparación y uso |
| JP7257387B2 (ja) * | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| KR20250005229A (ko) * | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
-
2021
- 2021-11-10 TW TW110141858A patent/TWI904281B/zh active
- 2021-11-11 US US17/524,632 patent/US11434222B2/en active Active
- 2021-11-11 UY UY0001039516A patent/UY39516A/es unknown
- 2021-11-12 US US18/252,611 patent/US20240018120A1/en active Pending
- 2021-11-12 IL IL301818A patent/IL301818B1/en unknown
- 2021-11-12 AU AU2021379081A patent/AU2021379081A1/en active Pending
- 2021-11-12 GE GEAP202116246A patent/GEP20257794B/en unknown
- 2021-11-12 EP EP25166976.8A patent/EP4574150A3/en active Pending
- 2021-11-12 HU HUE21811018A patent/HUE071543T2/hu unknown
- 2021-11-12 CR CR20230203A patent/CR20230203A/es unknown
- 2021-11-12 GE GEAP202516246A patent/GEAP202516246A/en unknown
- 2021-11-12 SI SI202130311T patent/SI4244208T1/sl unknown
- 2021-11-12 KR KR1020237015365A patent/KR20230107225A/ko active Pending
- 2021-11-12 PT PT218110187T patent/PT4244208T/pt unknown
- 2021-11-12 FI FIEP21811018.7T patent/FI4244208T3/fi active
- 2021-11-12 HR HRP20250644TT patent/HRP20250644T1/hr unknown
- 2021-11-12 PL PL21811018.7T patent/PL4244208T3/pl unknown
- 2021-11-12 UA UAA202301351A patent/UA130186C2/uk unknown
- 2021-11-12 ES ES21811018T patent/ES3025484T3/es active Active
- 2021-11-12 JP JP2023524567A patent/JP2023549051A/ja active Pending
- 2021-11-12 CN CN202180073621.0A patent/CN116547274B/zh active Active
- 2021-11-12 MA MA62148A patent/MA62148B1/fr unknown
- 2021-11-12 CN CN202512011225.8A patent/CN121824488A/zh active Pending
- 2021-11-12 MX MX2023005576A patent/MX2023005576A/es unknown
- 2021-11-12 WO PCT/EP2021/081522 patent/WO2022101412A1/en not_active Ceased
- 2021-11-12 LT LTEPPCT/EP2021/081522T patent/LT4244208T/lt unknown
- 2021-11-12 RS RS20250496A patent/RS66839B1/sr unknown
- 2021-11-12 AR ARP210103142A patent/AR124057A1/es unknown
- 2021-11-12 CA CA3196119A patent/CA3196119A1/en active Pending
- 2021-11-12 EP EP21811018.7A patent/EP4244208B1/en active Active
- 2021-11-12 DK DK21811018.7T patent/DK4244208T3/da active
-
2023
- 2023-04-04 ZA ZA2023/04134A patent/ZA202304134B/en unknown
- 2023-04-14 CO CONC2023/0004649A patent/CO2023004649A2/es unknown
- 2023-04-17 SA SA523440403A patent/SA523440403B1/ar unknown
- 2023-05-01 JO JOJO/P/2023/0091A patent/JOP20230091A1/ar unknown
- 2023-05-02 DO DO2023000086A patent/DOP2023000086A/es unknown
- 2023-05-09 CL CL2023001339A patent/CL2023001339A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3489238B1 (en) | Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders | |
| AU2017353310B2 (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as PDE2 inhibitors | |
| EP3724194B1 (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| CA3196119A1 (en) | A magl inhibitor | |
| AU2014368601B2 (en) | Quinazolin-THF-amines as PDE1 inhibitors | |
| CN111108109A (zh) | 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途 | |
| US20230067237A1 (en) | Caffeine inhibitors of mthfd2 and uses thereof | |
| EP3724196B9 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| CA3049820A1 (en) | Compounds for inhibiting lrrk2 kinase activity | |
| JP2026511698A (ja) | ＰＲＭＴ５のＭＴＡ協同的阻害剤としての５－アミノ－６，８－ジヒドロ－１Ｈ－フロ［３，４－ｄ］ピロロ［３，２－ｂ］ピリジン－２－カルボキサミド誘導体 | |
| CA3216629A1 (en) | Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents | |
| HK40100721A (en) | A magl inhibitor | |
| HK40100721B (en) | A magl inhibitor | |
| EA048915B1 (ru) | Ингибитор magl | |
| HK40006641A (en) | Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders | |
| HK40006641B (en) | Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders | |
| HK40041148B (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| HK40039957B (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| HK40039957A (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| OA19667A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. | |
| EA040675B1 (ru) | Ингибиторы активин-подобной рецепторной киназы | |
| HK1208023B (en) | 6-benzyl-6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c] pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c] pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241023 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241023 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241023 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251022 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251022 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251105 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260105 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260105 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260105 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260108 |